The estimated Net Worth of Patrick D Spangler is at least $907 Tysiąc dollars as of 5 June 2024. Mr. Spangler owns over 10,061 units of OptimizeRx Corp stock worth over $234,278 and over the last 6 years he sold OPRX stock worth over $527,544. In addition, he makes $145,348 as Independent Director at OptimizeRx Corp.
Patrick has made over 9 trades of the OptimizeRx Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 10,061 units of OPRX stock worth $73,244 on 5 June 2024.
The largest trade he's ever made was exercising 10,061 units of OptimizeRx Corp stock on 5 June 2024 worth over $73,244. On average, Patrick trades about 1,267 units every 103 days since 2018. As of 5 June 2024 he still owns at least 32,181 units of OptimizeRx Corp stock.
You can see the complete history of Mr. Spangler stock trades at the bottom of the page.
Patrick D. Spangler serves as Independent Director of the Company. Mr. Spangler presently serves as CFO of VigiLanz, a digital healthcare intelligence firm, and as a member of the board of directors of Lifespace Communities. He has more than 30 years of experience in the health care industry, executing domestic and international growth and exit strategies. He has helped lead high-performance, emerging growth firms, as well as large publicly-traded companies. Earlier, Mr. Spangler served as executive vice president and CFO of Healthland, an EHR company serving the critical access hospital market. He has also served as CFO at the point-of-care medical applications provider, Epocrates, that he helped bring public in 2011, and which was eventually acquired by Athenahealth. Prior to Epocrates, he was CFO of the ev3, a vascular therapy that went public in 2005 and then acquired by Covidien, as well as CFO of the medical device manufacturer, Empi, which was acquired by Encore Medical. Aside from that provided above, Mr. Spangler does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.
As the Independent Director of OptimizeRx Corp, the total compensation of Patrick Spangler at OptimizeRx Corp is $145,348. There are 7 executives at OptimizeRx Corp getting paid more, with Stephen Silvestro having the highest compensation of $1,210,200.
Patrick Spangler is 64, he's been the Independent Director of OptimizeRx Corp since 2018. There are 2 older and 9 younger executives at OptimizeRx Corp. The oldest executive at OptimizeRx Corp is Gus Halas, 69, who is the Chairman of the Board.
Patrick's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.
Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff oraz David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.
optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.
OptimizeRx Corp executives and other stock owners filed with the SEC include: